Early outcomes following low dose naltrexone enhancement of opioid detoxification

American Journal on Addictions

Volumn 18, Issue 2, 2009, Pages 109-116

  Mannelli, Paolo ^a   Patkar, Ashwin A ^a   Peindl, Kathleen ^a   Gottheil, Edward ^b   Wu, Li Tzy ^a   Gorelick, David A ^c  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; CANNABIS; METHADONE; NALTREXONE; OPIATE; PLACEBO; NARCOTIC AGENT; NARCOTIC ANTAGONIST;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DETOXIFICATION; DIAGNOSTIC APPROACH ROUTE; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; HUMAN; LOW DRUG DOSE; MALE; OPIATE ADDICTION; OUTCOMES RESEARCH; OUTPATIENT; RANDOMIZED CONTROLLED TRIAL; MULTICENTER STUDY; PATIENT CARE; TREATMENT OUTCOME; WITHDRAWAL SYNDROME;

ADULT; CONTINUITY OF PATIENT CARE; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; METHADONE; NALTREXONE; NARCOTIC ANTAGONISTS; NARCOTICS; OPIOID-RELATED DISORDERS; PLACEBOS; SUBSTANCE WITHDRAWAL SYNDROME; TREATMENT OUTCOME;

EID: 66549114739     PISSN: 10550496     EISSN: 15210391     Source Type: Journal    
DOI: 10.1080/10550490902772785     Document Type: Article

References (47)

1. Mattick R, Hall W. Are detoxification programmes effective? Lancet. 1996;347:97-100.
2. O'Connor P. Methods of detoxification and their role in treating patients with opioid dependence. JAMA. 2005;294:961-963.
3. Bradley BP, Phillips G, Green L, Gossop M. Circumstances surrounding the initial lapse to opiate use following detoxification. Br J Psychiatry. 1989;154:354-359.
4. Unnithan S, Gossop M, Strang J. Factors associated with relapse among opiate addicts in an out-patient detoxification programme. Br J Psychiatry. 1992;161:654-657.
5. Lowinson JH, Marion I, Joseph H, Langrod J, Salsitz EA, Payte JT. Methadone maintenance. In: Lowinson JH, Ruiz P, Millman RB, Langrod JG, eds. Substance abuse: a comprehensive textbook, 4th edition. Baltimore: Lippincott, Williams & Wilkins; 2005:616-640.
6. Broers B, Giner F, Dumont P, Mino A. Inpatient opiate detoxification in Geneva: follow-up at 1 and 6 months. Drug Alcohol Depend. 2000;58:85-92.
7. GossopM, GreenL,PhillipsG, Bradley B. What happensto opiate addicts immediately after treatment: a prospective study. Br Med J (Clin Res Ed). 1987;294:1377-1380.
8. Collins ED, Kleber HD, Whittington RA, Heitler NE. Anesthesia-assisted vs buprenorphine- or clonidine-assisted heroin detoxification and naltrexone induction: a randomized trial. JAMA. 2005;294:903-913.
9. De Jong CA, Laheij RJ, Krabbe PF. General anaesthesia does not improve outcome in opioid antagonist detoxification treatment: a randomized controlled trial. Addiction. 2005;100:206-215.
10. Substance Abuse and Mental Health Services Administration Treatment Episode and Data Set Highlights-2005; February 2007.
11. Digiusto E, Lintzeris N, Breen C, et al. Short-term outcomes of five heroin detoxification methods in the Australian NEPOD Project. Addict Behav. 2005;30:443-456.
12. Myrick H, Anton R, Kasser CL. Management of intoxication and withdrawal: General principles. In: Graham AW, Schultz TK, Mayo-Smith MF, eds. Principles of addiction medicine, 3rd edition Chevy Chase: American Society of Addiction Medicine; 2003:611-618.
13. McLellan AT, Woody GE, Metzger D. Evaluating the effectiveness of addiction treatments: Reasonable expectations, appropriate comparisons. The Milbank Quarterly. 1996;74:51-85.
14. McCambridge J, Gossop M, Beswick T, et al. In-patient detoxification procedures, treatment retention, and post-treatment opiate use: comparison of lofexidine + naloxone, lofexidine + placebo, and methadone. Drug Alcohol Depend. 2007;88:91-95.
15. Kornør H, Waal H. From opioid maintenance to abstinence: a literature review. Drug Alcohol Rev. 2005;24:267-274.
16. Chutuape MA, Jasinski DR, Fingerhood MI, Stitzer ML. One-, three-, and six-month outcomes after brief inpatient opioid detoxification. Am J Drug Alcohol Abuse. 2001;27:19-44.
17. Fagan RW, Mauss AL. Padding the revolving door: an initial assessment of the Uniform Alcoholism and Intoxication Treatment Act in practice. Social Problems. 1978;26:232-247.
18. O'Toole TP, Strain EC, Wand G, McCaul ME, Barnhart M. Outpatient treatment entry and health care utilization after a combined medical/substance abuse intervention for hospitalized medical patients. J Gen Intern Med. 2002;17:334-340.
19. Nunes EV, Rothenberg JL, Sullivan MA, Carpenter KM, Kleber HD. Behavioral therapy to augment oral naltrexone for opioid dependence: a ceiling on effectiveness? Am J Drug Alcohol Abuse. 2006;32:503-517.
20. Sullivan MA, Garawi F, Bisaga A, et al. Management of relapse in naltrexone maintenance for heroin dependence. Drug Alcohol Depend. 2007;91:289-292.
21. Gowing L, Ali R, White J. Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal. Cochrane Database Syst Rev. 2006;19:CD002022.
22. O'Connor PG, Kosten TR. Rapid and ultrarapid opioid detoxification techniques. JAMA. 1998;279:229-234.
23. Wang HY, Friedman E, Olmstead MC, Burns LH. Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gbetagamma signaling. Neuroscience. 2005;135:247-261.
24. Webster LR, Butera PG, Moran LV, Wu N, Burns LH, Friedmann N. Oxytrex minimizes physical dependence while providing effective analgesia: a randomized controlled trial in low back pain. J Pain. 2006; 7:937-946.
25. Mannelli P, Gottheil E, Buonanno A, De Risio S. Use of very low-dose naltrexone during opiate detoxification. J Addict Dis. 2003;22:63-70.
26. Rea F, Bell JR, Young MR, Mattick RP. A randomised, controlled trial of low dose naltrexone for the treatment ofopioid dependence. Drug Alcohol Depend. 2004;75:79-88.
27. Mannelli P, Patkar AA, Peindl K, Gorelick DA, Wu LT, Gottheil E. Very low dose naltrexone addition in opioid detoxification: A randomized, controlled trial. Addiction Biology. In press. 2008 Aug 19. [Epub ahead of print]
28. American Psychiatric Association. Diagnostic criteria from DSM-IV-TR/American Psychiatric Association. American Psychiatric Association: Washington, D.C; 2000.
29. McLellan AT, Kushner H, Metzger D, et al. The Fifth Edition of the Addiction Severity Index. J Subst Abuse Treat. 1992;9:199-213.
30. Handelsman L, Cochrane KJ, Aronson MJ, Ness R, Rubinstein KJ, Kanof PD. Two new rating scales for opiate withdrawal. Am J Drug Alcohol Abuse. 1987;13:293-308.
31. Kanof PD, Handelsman L, Aronson MJ, Ness R, Cochrane KJ, Rubinstein KJ. Clinical characteristics of naloxone-precipitated withdrawal in human opioid-dependent subjects. J Pharmacol Exp Ther. 1992;260:355-363.
32. McLellan AT, Alterman AI, Cacciola J, Metzger D, O'Brien C. A new measure of substance abuse treatment. Initial studies of the treatment services review. J Nerv Ment Dis. 1992;180:101-110.
33. Sobell LC, Brown J, Leo GI, Sobell MB. The reliability of the Alcohol Timeline Followback when administered by telephone and by computer. Drug Alcohol Depend. 1996;42:49-54.
34. Cook RJ, Sackett DL. The number needed to treat: a clinically useful measure of treatment effect. BMJ. 1995;310:452-454.
35. Gossop M, Green L, Phillips G, Bradley B. Lapse, relapse and survival among opiate addicts after treatment. A prospective follow-up study. Br J Psychiatry. 1989;154:348-353.
36. Mannelli P, Patkar AA, Peindl K, Murray HW, Wu LT, Hubbard K. Effectiveness of low-dose naltrexone in the post-detoxification treatment of opioid dependence. J Clin Psychopharmacol. 2007;27:468-474.
37. Stenbacka M, Beck O, Leifman A, Romelsjö A, Helander A. Problem drinking in relation to treatment outcome among opiate addicts in methadone maintenance treatment. Drug Alcohol Rev. 2007;26:55-63.
38. Connock M, Juarez-Garcia A, Jowett S, et al. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess. 2007;11:1-171.
39. Haney M. Opioid antagonism of cannabinoid effects: differences between marijuana smokers and nonmarijuana smokers. Neuropsychopharmacology 2007;32:1391-1403.
40. Justinova Z, Tanda G, Munzar P, Goldberg SR. The opioid antagonist naltrexone reduces the reinforcing effects of Delta 9 tetrahydrocannabinol (THC) in squirrel monkeys. Psychopharmacology (Berl.). 2004;173:186-194.
41. Modesto-Lowe V, Fritz EM. The opioidergic-alcohol link: implications for treatment. CNS Drugs. 2005;19:693-707.
42. Hoffmann N, Miller N. Perspectives of effective treatment for alcohol and drug disorders. Psychiatr Clin North Am. 1993;16:127-140.
43. McCusker J, Goldstein R, Bigelow C, Zorn M. Psychiatric status and HIV risk reduction among residential drug abuse treatment clients. Addiction. 1995;90:1377-1387.
44. Smart RG, Finley J, Funston R. The effectiveness of post-detoxication referrals: effects on later detoxication admissions, drunkenness and criminality. Drug Alcohol Depend. 1977;2:149-155.
45. Strain EC, Stitzer ML, Bigelow GE. Early treatment time course of depressive symptoms in opiate addicts. J Nerv Ment Dis. 1991;179:215-221.
46. Tennant FS, Jr. Benefits of recurrent, outpatient heroin detoxification. Int J Addict. 1985;20:1685-1691.
47. Comer SD, Sullivan MA, Hulse GK. Sustained-release naltrexone: novel treatment for opioid dependence. Expert Opin Investig Drugs. 2007;16:1285-1294.